DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Beck J, Bajetta E, Escudier B, Negrier S, Keilholz U, Szczylik C, Mersmann S, Burock K, Erlandsson F, Huber C. investigators.
ftE-As. A large open-label, non-comparative, phase III study
of the multi-targeted kinase inhibitor Sorafenib in European patients with
advanced renal cell carcinoma.
Eur J Cancer 2007; 5 (S 300)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.